PT3682889T - Modulação de ativação de inflamassoma de células supressoras derivadas de mieloide para tratamento de gvdh - Google Patents
Modulação de ativação de inflamassoma de células supressoras derivadas de mieloide para tratamento de gvdhInfo
- Publication number
- PT3682889T PT3682889T PT201539491T PT20153949T PT3682889T PT 3682889 T PT3682889 T PT 3682889T PT 201539491 T PT201539491 T PT 201539491T PT 20153949 T PT20153949 T PT 20153949T PT 3682889 T PT3682889 T PT 3682889T
- Authority
- PT
- Portugal
- Prior art keywords
- myeloid
- modulating
- tumor
- suppressor cells
- derived suppressor
- Prior art date
Links
- 108010034143 Inflammasomes Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0648—Splenocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2313—Interleukin-13 (IL-13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201990P | 2015-08-06 | 2015-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3682889T true PT3682889T (pt) | 2023-03-09 |
Family
ID=56686964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT201539491T PT3682889T (pt) | 2015-08-06 | 2016-08-05 | Modulação de ativação de inflamassoma de células supressoras derivadas de mieloide para tratamento de gvdh |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10894061B2 (OSRAM) |
| EP (3) | EP3682889B1 (OSRAM) |
| JP (3) | JP6927499B2 (OSRAM) |
| CN (2) | CN114790447A (OSRAM) |
| AU (2) | AU2016303622B2 (OSRAM) |
| CA (1) | CA2993806A1 (OSRAM) |
| ES (2) | ES2939534T3 (OSRAM) |
| PT (1) | PT3682889T (OSRAM) |
| WO (1) | WO2017024213A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2993806A1 (en) | 2015-08-06 | 2017-02-09 | Regents Of The University Of Minnesota | Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor |
| FR3100715B1 (fr) * | 2019-09-12 | 2023-09-29 | Francais Du Sang Ets | Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte |
| WO2022216615A1 (en) * | 2021-04-05 | 2022-10-13 | Rhode Island Hospital | Compositions and methods for the prevention or treatment of rheumatoid arthritis |
| CN113707223A (zh) * | 2021-04-21 | 2021-11-26 | 吴安华 | 一种预测肿瘤炎性小体活性状态及治疗敏感性的基因集系统及方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040136973A1 (en) | 2002-11-07 | 2004-07-15 | Eliezer Huberman | Human stem cell materials and methods |
| EP2300000A1 (en) | 2008-07-03 | 2011-03-30 | University of Massachusetts | Methods and compositions for reducing inflammation and treating inflammatory disorders |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| US20120082688A1 (en) * | 2008-11-26 | 2012-04-05 | Mount Sinai School Of Medicine | In Vitro Generation of Myeloid Derived Suppressor Cells |
| EP2515919A2 (en) * | 2009-12-22 | 2012-10-31 | Mount Sinai School of Medicine | Methods of using small compounds to enhance myeloid derived suppressor cell function for treating autoimmune diseases |
| US20140377278A1 (en) | 2012-01-10 | 2014-12-25 | Yale University | Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders |
| AR095882A1 (es) * | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| WO2015016178A1 (ja) | 2013-07-29 | 2015-02-05 | 国立大学法人鹿児島大学 | １，５－ｄ－アンヒドロフルクトースを含むアポトーシス関連スペック様カード蛋白質の機能阻害薬 |
| MX393750B (es) * | 2014-12-31 | 2025-03-24 | Checkmate Pharmaceuticals Inc | Inmunoterapia antitumoral combinada. |
| PL3656443T3 (pl) * | 2015-01-21 | 2022-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | Zastosowanie agonisty trl i środka anty-cd47 do wzmocnienia fagotocytozy komórek nowotworowych |
| CA2993806A1 (en) * | 2015-08-06 | 2017-02-09 | Regents Of The University Of Minnesota | Modulating inflammasome activation of myeloid-derived supperssor cells for treating gvhd or tumor |
| US11047114B2 (en) | 2015-11-13 | 2021-06-29 | Qf Technologies As | Method and device to collect water |
| GB201721185D0 (en) * | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| CN112646777B (zh) * | 2020-12-31 | 2022-11-04 | 广州医科大学 | 一种扩增髓系来源的抑制性细胞的方法 |
-
2016
- 2016-08-05 CA CA2993806A patent/CA2993806A1/en active Pending
- 2016-08-05 EP EP20153949.1A patent/EP3682889B1/en active Active
- 2016-08-05 CN CN202210388064.8A patent/CN114790447A/zh active Pending
- 2016-08-05 ES ES20153949T patent/ES2939534T3/es active Active
- 2016-08-05 CN CN201680046264.8A patent/CN108883131B/zh active Active
- 2016-08-05 PT PT201539491T patent/PT3682889T/pt unknown
- 2016-08-05 AU AU2016303622A patent/AU2016303622B2/en active Active
- 2016-08-05 JP JP2018506141A patent/JP6927499B2/ja active Active
- 2016-08-05 EP EP16751781.2A patent/EP3331538B1/en active Active
- 2016-08-05 ES ES16751781T patent/ES2789574T3/es active Active
- 2016-08-05 EP EP22215685.3A patent/EP4218776A3/en not_active Withdrawn
- 2016-08-05 US US15/747,902 patent/US10894061B2/en active Active
- 2016-08-05 WO PCT/US2016/045739 patent/WO2017024213A1/en not_active Ceased
-
2020
- 2020-12-11 US US17/119,832 patent/US12234480B2/en active Active
-
2021
- 2021-07-19 JP JP2021118749A patent/JP7235259B2/ja active Active
-
2022
- 2022-09-09 AU AU2022228188A patent/AU2022228188A1/en active Pending
-
2023
- 2023-02-15 JP JP2023021455A patent/JP2023053338A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3331538A1 (en) | 2018-06-13 |
| HK1256917A1 (en) | 2019-10-04 |
| CA2993806A1 (en) | 2017-02-09 |
| JP2023053338A (ja) | 2023-04-12 |
| AU2016303622B2 (en) | 2022-07-07 |
| EP3682889A1 (en) | 2020-07-22 |
| EP4218776A2 (en) | 2023-08-02 |
| CN108883131B (zh) | 2022-04-29 |
| ES2939534T3 (es) | 2023-04-24 |
| ES2789574T3 (es) | 2020-10-26 |
| AU2016303622A1 (en) | 2018-02-22 |
| US20180214483A1 (en) | 2018-08-02 |
| JP2018536620A (ja) | 2018-12-13 |
| AU2022228188A1 (en) | 2022-09-29 |
| WO2017024213A1 (en) | 2017-02-09 |
| AU2016303622A8 (en) | 2018-05-31 |
| EP3682889B1 (en) | 2023-02-01 |
| CN108883131A (zh) | 2018-11-23 |
| JP2021167345A (ja) | 2021-10-21 |
| CN114790447A (zh) | 2022-07-26 |
| JP6927499B2 (ja) | 2021-09-01 |
| US20210128612A1 (en) | 2021-05-06 |
| US12234480B2 (en) | 2025-02-25 |
| JP7235259B2 (ja) | 2023-03-08 |
| US10894061B2 (en) | 2021-01-19 |
| EP3331538B1 (en) | 2020-03-11 |
| EP4218776A3 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275663A (en) | Cancer treatment methods | |
| SG10202110594UA (en) | Methods of treating tumor | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL253795A0 (en) | Methods for treating cancer using activated t cells | |
| IL255189A0 (en) | Cancer treatment methods | |
| SG10201913409VA (en) | Methods for solid tumor treatment | |
| ZA201802831B (en) | Composition for the treatment of igf-1r expressing cancer | |
| IL259996A (en) | Combinations for cancer treatment | |
| LT3122358T (lt) | Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui | |
| PT3261726T (pt) | Composição para o tratamento do acne | |
| IL262342A (en) | Cancer treatment methods | |
| EP3177308A4 (en) | Use of peptides that block metadherin-snd1 interaction as treatment for cancer | |
| IL263059A (en) | A method for treating cancer by targeting myeloid-derived suppressor cells | |
| IL259781A (en) | Uses of pyrimido-pyridazinones to treat cancer | |
| PT3682889T (pt) | Modulação de ativação de inflamassoma de células supressoras derivadas de mieloide para tratamento de gvdh | |
| EP3108884A4 (en) | Composition for prevention or treatment of treatment-resistant cancer | |
| IL277377B (en) | Prohemostatic proteins for the treatment of bleeding | |
| SG11202005163PA (en) | Methods of treating cancer | |
| ZA201606921B (en) | Use of xanthophylls for the treatment of cancers | |
| EP3389670A4 (en) | METHODS OF TREATING BREAST CANCER | |
| IL269123A (en) | Methods of treating cancer | |
| IL257433B (en) | Combinations of lanvatinib, ifosfamide and etoposide for the treatment of tumors | |
| PT3524255T (pt) | Composição para o tratamento do acne | |
| GB201512723D0 (en) | Treatment of cancer | |
| GB201507928D0 (en) | Treatment of cancer |